

Version 1.0.3

Submission

[Home](#) > [Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	02/01/2019
Deadline Date	31/01/2019
Date Submitted	23/01/2019
Type	Performance In Delivering
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 11 of 11.
Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
34472	14/YH/1056	147421	AB10004 Study- A Multicenter, Randomised, Open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of mastinib with dexamethasone, gemcitabine with dexamethasone and the combination of mastinib, gemcitabine and dexametha	Number Agreed	4	4	Date Agreed	06/06/2017	1	28/02/2018	1	Withdrawn By Sponsor	Sponsor closed as study futile
34473	16/EM/0332	205699	MAXIMISE: Managing axial manifestations in psoriatic arthritis with secukinumab, a randomised, double-blind, placebo-controlled, multicentre, 52 week study to assess the efficacy and safety of Secukinumab 150mg or 300mg s.c. in patients with active p	Number Agreed	4	4	Not Available / Not Agreed			28/03/2018	4	Recruitment Finished	
34474	13/LO/1557	135995	CALM-NET: A Phase 4, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving D	Number Agreed	2	2	Not Available / Not Agreed			07/07/2018	0	Recruitment Finished	Rare pt population, difficult to screen/recruit eligible pts
34475	17/LO/0441	222471	KEYNOTE-604 MK-3475: A phase III randomised double-blind placebo-controlled trial of pembrolizumab (MK-3475) in combination with etoposide/platinum (Cisplatin or Carboplatin) for the first-line treatment of subjects with extensive stage small cell lu	Number Agreed	4	4	Date Agreed	05/03/2018	1	10/07/2018	3	Recruitment Finished	study reached overall recruitment target
34476	14/NW/1258	161891	ARAMIS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high risk non-metastatic castration-resistant prostate cancer.	Number Agreed	4	4	Not Available / Not Agreed			09/03/2018	1	Recruitment Finished	
34477	16/LO/1106	207909	A randomised double blind phase III study of Pembrolizumab () plus Chemotherapy vs Placebo plus Chemotherapy for previously untreated inoperable locally recurrent or metastatic triple negative breast cancer (keynote 355)	Number Agreed	4	4	Not Available / Not Agreed			03/07/2018	0	Recruitment Finished	Although C&C issued, not activated for recruitment due to capacity issues within delivery team - sponsor aware.
34478	17/LO/0347	221524	KEYNOTE 522 - A Phase III randomized double blind study to evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	Number Agreed	4	4	Not Available / Not Agreed			03/07/2018	0	Recruitment Finished	Overall study recruitment reached before site could recruit
34479	17/LO/0825	223457	GS-US-445-4189 A randomised phase 2 double-blind placebo-controlled study to assess the safety and efficacy of filgotinib GS-	Number Agreed	2	2	Date Agreed	01/04/2018	0	05/09/2018	0	Recruitment Finished	pts not ill enough to meet inc/exc criteria

